Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 96871623 | 9687162 | 3 | F | 20131113 | 20131113 | 20160902 | EXP | US-ROCHE-1303273 | ROCHE | 0.00 | F | Y | 0.00000 | 20160902 | MD | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 96871623 | 9687162 | 1 | PS | XOLAIR | OMALIZUMAB | 1 | Subcutaneous | U | 103976 | 300 | MG | ||||||||
| 96871623 | 9687162 | 2 | C | LEVAQUIN | LEVOFLOXACIN | 1 | Unknown | X 14 DAYS | 0 | 500 | MG | QD | |||||||
| 96871623 | 9687162 | 3 | C | KENALOG | TRIAMCINOLONE ACETONIDE | 1 | Intramuscular | 0 | 150 | MG |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 96871623 | 9687162 | 1 | Asthma |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 96871623 | 9687162 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 96871623 | 9687162 | Asthma | |
| 96871623 | 9687162 | Bronchitis | |
| 96871623 | 9687162 | Conjunctivitis allergic | |
| 96871623 | 9687162 | Nasal discharge discolouration | |
| 96871623 | 9687162 | Nasal mucosal disorder | |
| 96871623 | 9687162 | Productive cough | |
| 96871623 | 9687162 | Rhinitis allergic | |
| 96871623 | 9687162 | Rhonchi | |
| 96871623 | 9687162 | Wheezing |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |